Literature DB >> 15382214

Transplantation for hilar cholangiocarcinoma.

Julie K Heimbach1, Michael G Haddock, Steven R Alberts, Scott L Nyberg, Michael B Ishitani, Charles B Rosen, Gregory J Gores.   

Abstract

1. Patients with primary sclerosing cholangitis (PSC) have a 8 to 12% risk of developing cholangiocarcinoma (CCA). 2. Cytologic techniques for aneuploidy such as digital image analysis and fluorescence in situ hybridization increase the detection rate for CCA. 3. Survival following resection for CCA is 20% to 40% at 5 years. 4. Survival following liver transplantation for unresectable, perihilar CCAs, mass lesion if present <3 cm, is greater than 80% at 5 years. 5. Patients with intrahepatic CCAs are not eligible for liver transplantation.

Entities:  

Mesh：

Year:  2004        PMID： 15382214     DOI： 10.1002/lt.20266

Source DB:  PubMed          Journal:  Liver Transpl        ISSN： 1527-6465            Impact factor:   5.799


  21 in total

1.  Pathology: Does nodal micrometastasis impact outcome in biliary cancer?

Authors:  Michael A Silva; Peter J Friend
Journal:  Nat Rev Clin Oncol       Date:  2010-12       Impact factor: 66.675

2.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

Authors:  Al B Benson; Thomas A Abrams; Edgar Ben-Josef; P Mark Bloomston; Jean F Botha; Bryan M Clary; Anne Covey; Steven A Curley; Michael I D'Angelica; Rene Davila; William D Ensminger; John F Gibbs; Daniel Laheru; Mokenge P Malafa; Jorge Marrero; Steven G Meranze; Sean J Mulvihill; James O Park; James A Posey; Jasgit Sachdev; Riad Salem; Elin R Sigurdson; Constantinos Sofocleous; Jean-Nicolas Vauthey; Alan P Venook; Laura Williams Goff; Yun Yen; Andrew X Zhu
Journal:  J Natl Compr Canc Netw       Date:  2009-04       Impact factor: 11.908

3.  Hilar cholangiocarcinoma: expert consensus statement.

Authors:  John C Mansour; Thomas A Aloia; Christopher H Crane; Julie K Heimbach; Masato Nagino; Jean-Nicolas Vauthey
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

4.  Liver transplantation for hilar cholangiocarcinoma (h-CCA): is it the right time?

Authors:  Thomas Resch; Hannah Esser; Benno Cardini; Benedikt Schaefer; Heinz Zoller; Stefan Schneeberger
Journal:  Transl Gastroenterol Hepatol       Date:  2018-07-04

5.  Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: a meta-analysis.

Authors:  Shang-Long Liu; Zi-Fang Song; Qing-Gang Hu; Duo Shan; Shao-Bo Hu; Jun Li; Qi-Chang Zheng
Journal:  Front Med China       Date:  2010-11-16

6.  Surgical management trends for cholangiocarcinoma in the USA 1998-2009.

Authors:  Jamie E Anderson; Alan W Hemming; David C Chang; Mark A Talamini; Kristin L Mekeel
Journal:  J Gastrointest Surg       Date:  2012-07-31       Impact factor: 3.452

7.  Primary sclerosing cholangitis treated by endoscopic biliary dilation: review and long-term follow-up evaluation.

Authors:  G Kenneth Johnson; Kia Saeian; Joseph E Geenen
Journal:  Curr Gastroenterol Rep       Date:  2006-04

Review 8.  Liver Transplantation for Cholestatic Liver Diseases in Adults.

Authors:  Vandana Khungar; David Seth Goldberg
Journal:  Clin Liver Dis       Date:  2015-10-23       Impact factor: 6.126

9.  Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database.

Authors:  Valery Vilchez; Malay B Shah; Michael F Daily; Luis Pena; Ching-Wei D Tzeng; Daniel Davenport; Peter J Hosein; Roberto Gedaly; Erin Maynard
Journal:  HPB (Oxford)       Date:  2016-01-07       Impact factor: 3.647

10.  New advances in the management of biliary tract cancer.

Authors:  John Bridgewater; Charles Imber
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.